logo

Fibrocell Science, Inc. (FCSC)



Trade FCSC now with
  Date
  Headline
9/12/2019 7:41:20 PM Castle Creek Pharmaceutical Holdings Announces Agreement To Acquire Fibrocell
5/29/2019 8:14:22 AM Fibrocell Gets FDA RMAT Designation For FCX-007 For Treatment Of RDEB
3/27/2019 7:34:44 AM Fibrocell Science Says Addl Data From Phase 1/2 Clinical Trial Shows FCX-007 Continues To Be Well Tolerated
11/13/2018 8:29:33 AM Fibrocell Science 9-month Loss Per Share $1.31 Vs Loss $7.92 Per Share Last Year
10/25/2018 8:13:03 AM Fibrocell Gets Guidance From FDA On Phase 3 Clinical Trial Design For FCX-007; To Submit Phase 3 Protocol To FDA In Q4
9/25/2018 8:03:07 AM Fibrocell Awarded $1.4 Mln FDA Orphan Grant For FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa
9/25/2018 8:02:17 AM Fibrocell Bags $1.4 Mln FDA Orphan Grant For FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa
9/5/2018 8:11:59 AM Fibrocell Announces FDA Fast Track Designation Of FCX-013 For Treatment Of Moderate To Severe Localized Scleroderma
8/9/2018 8:12:13 AM Fibrocell Science 6-month Loss Per Share $1.03 Vs Loss $7.82 Last Year
7/5/2018 4:07:14 PM Fibrocell Closes $4 Mln Registered Direct Offering
5/29/2018 9:21:29 AM Fibrocell Reports $6.0 Mln Registered Direct Offering Priced At-the-Market
5/24/2018 8:57:27 AM Fibrocell Announces 1-for-5 Reverse Stock Split
5/21/2018 7:06:16 AM Fibrocell Provides Update On Interim Results And Progress Of Its Phase 1/2 Clinical Trial Of FCX-007
5/10/2018 8:15:11 AM Fibrocell Science Q1 Loss/shr Narrows To $0.11 From $0.60 Last Year
4/18/2018 8:02:28 AM Fibrocell Science Trading Halted; Pending News
3/6/2018 8:11:38 AM Fibrocell Science Reports FDA Allowance Of IND Application For FCX-013
2/5/2018 8:15:24 AM Fibrocell Says Submits IND Application For FCX-013 For Treatment Of Moderate To Severe Localized Scleroderma
1/30/2018 8:09:22 AM Fibrocell Gets FDA Allowance To Begin Pediatric Enrollment In Phase 2 Portion Of Phase 1/2 Clinical Trial Of FCX-007